Archived explainer. For the current picture see today's SMMT page.
SUMMIT THERAPEUTICS (SMMT) is drawing unusual attention today. Our newswire has captured 5 stories on SMMT across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 60/100).
Summit Therapeutics (SMMT) shares are moving higher in early trading, up more than 3.6% as of the last print at $15.05. The upward movement follows updated data from the company’s Phase III HARMONi trial of ivonescimab, which showed consistent overall survival benefits in both Western and Asian patients with EGFR-mutated non-small cell lung cancer (NSCLC). The results are being viewed as supportive of the ongoing U.S. Food and Drug Administration (FDA) review of the drug, with a Prescription Drug User Fee Act (PDUFA) decision date set for November 14, 2026.
Summit Therapeutics released updated results from the HARMONi trial, which evaluated ivonescimab in combination with chemotherapy. The latest analysis confirmed a consistent overall survival benefit across both Western and Asian patient groups, reinforcing the drug’s potential as a treatment for EGFR-mutated NSCLC. The updated data were highlighted in multiple reports, including a Form 8-K filed on July 22, 2026, and press releases from several outlets. The results are being seen as a positive development ahead of the FDA’s final decision on the Biologics License Application (BLA), which is scheduled for late November 2026.
The stock opened at $14.47, a 1.1% gap down from the previous close, but quickly reversed to trade higher. The session high reached $15.72 at 7:25 AM ET, while the low was $14.46. Trading volume has been light so far, with 0.1 million shares exchanged, which is below the 3-month daily average. Over the past 30 days, sentiment has improved slightly, rising from an average of 55 out of 100 to 59 out of 100 in the last seven days. Additionally, recent insider activity has been bullish, with five insider purchases totaling $103.6 million in the last 90 days, most recently on June 12.
The FDA’s PDUFA decision on November 14 will be the next key event for investors. Additionally, coverage breadth and market reaction to the updated trial data will be important to monitor in the coming sessions.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Summit Therapeutics reported updated Phase III HARMONi trial data showing consistent overall survival benefits for ivonescimab, supporting its ongoing FDA review ahead of a November 2026 decision.
Summit Therapeutics’ Phase III HARMONi study shows ivonescimab plus chemotherapy delivers a consistent overall survival benefit to both Western and Asian patients with EGFR-mutated NSCLC. The latest analysis demonstrates aligned hazard ratios and durable safety results, strengthening prospects for FDA review and global adoption.
Summit Therapeutics (SMMT) stock slips as the company updates data from a late-stage trial for a lung cancer drug developed with Akeso (AKESF). Read more here.
Filed: 2026-07-22 AccNo: 0001599298-26-000058 Size: 2 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
The June 2026 analysis followed Western patients for 23.2 months; the FDA’s PDUFA goal action date is Nov. 14 for Summit’s BLA filing.
More on SMMT: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier SMMT move explainers: 2026-07-24 · 2026-07-23 · 2026-07-22